Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2005 Aug;6(9):1565-72.

Review of atazanavir: a novel HIV protease inhibitor.

Author information

1
HIV Clinical Unit/FundaciĆ³ Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.

Abstract

Atazanavir is a novel and potent protease inhibitor that differs from other protease inhibitors because of its good gastrointestinal tolerability, once-daily dosing, low pill burden and it does not seem to cause insulin resistance or lipid elevations in short-term use. Atazanavir produces an increase in indirect bilirubin levels, which is not related to hepatotoxicity. The incidence of atazanavir-related hyperbilirubinaemia does not seem to be increased in hepatitis B or C coinfection. I50L is atazanavir's signature mutation. It has been shown in previously treated patients that resistance is likely when three or more protease inhibitor resistance-related primary mutations are present.

PMID:
16086644
DOI:
10.1517/14656566.6.9.1565
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center